Bayer has opened a new $142 million manufacturing facility in Berlin that features state-of-the-art technology, innovative production, and automated processes. The production facility is based on a platform technology that covers a wide range of chemically and biologically based parenteral products.
The highly digitized manufacturing process enables safe, fast, and sterile formulation, filling, and freeze-drying of pharmaceuticals, while the automated, robot-based filling machine combines efficient and reliable production of medications, aiming to bring them from concept to market and ultimately to the patients even faster.
The facility will serve critical manufacturing areas with high medical demand, such as products in the field of ophthalmology. A part of a billion dollar investment program through which Bayer is strengthening its global pharmaceutical production network and innovative capabilities, it is intended to supply markets in the U.S., Europe, and China.
“It is of crucial importance that Germany and Europe pursue a clear strategy of a future-oriented innovation policy,” says Stefan Oelrich, a member of the board of Bayer and head of its pharmaceuticals division. “Bayer is investing here in research and production to secure future business while strengthening the innovative power in the region.”
